TrialThe Lancet. Oncology2017

Idelalisib or placebo in combination with bendamustine and rituximab in patients with relapsed or refractory chronic lymphocytic leukaemia: interim results from a phase 3, randomised, double-blind, placebo-controlled trial.

Andrew D Zelenetz et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.